Heghine Khachatryan: New Evidence in Secondary Stroke Prevention: Cilostazol + Aspirin vs Ticagrelor + Aspirin
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by International Journal of Stroke on LinkedIn:
“New evidence in secondary stroke prevention
A recent study published in the International Journal of Stroke reports that cilostazol plus aspirin significantly reduces recurrent stroke, myocardial infarction, and vascular death, with comparable efficacy to ticagrelor plus aspirin in the acute-phase treatment of large-vessel disease.
Why this matters
• Provides an alternative dual antiplatelet strategy with proven effectiveness
• Particularly relevant for patients with high bleeding risk, intolerance, or contraindications to potent P2Y12 inhibitors
• Highlights the growing role of cilostazol-based regimens beyond East Asian populations
-This study adds valuable data to ongoing discussions on individualized antiplatelet therapy after ischemic stroke and reinforces the need to balance efficacy with safety.
Full article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel disease”
Quoting International Journal of Stroke‘s post:
“Study finds cilostazol plus aspirin reduced recurrent stroke, MI, and vascular death with a comparable rate to ticagrelor plus aspirin
However, cilostazol plus aspirin showed significantly lower rates of hemorrhagic complications and better tolerability
Read more here.”
Title: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk ahmed et al.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting
-
Jun 1, 2026, 13:23Skye Collado: Miller-Keystone Blood Center Expands Community Impact Through the Addition of New Bloodmobiles
-
Jun 1, 2026, 12:37Rutuja Mahadik: Anemia is More Than Just Feeling Tired
-
Jun 1, 2026, 12:36Ankur Jindal: Large-Vessel Inflammation and Immune Dysregulation in Wiskott–Aldrich Syndrome
-
Jun 1, 2026, 12:35Shadi Almassri: Conditions That Can Cause False High or False Low HbA1c Results
-
Jun 1, 2026, 12:22Ed Davidson: Clot Removing Technology That Can Change the Game